nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—PPARG—urinary bladder cancer	0.527	1	CbGaD
Pioglitazone—SLCO1B3—Methotrexate—urinary bladder cancer	0.0544	0.217	CbGbCtD
Pioglitazone—PTGS1—Etoposide—urinary bladder cancer	0.0352	0.141	CbGbCtD
Pioglitazone—SLCO1B1—Methotrexate—urinary bladder cancer	0.0317	0.127	CbGbCtD
Pioglitazone—CYP3A4—Thiotepa—urinary bladder cancer	0.0303	0.121	CbGbCtD
Pioglitazone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0243	0.0972	CbGbCtD
Pioglitazone—CYP2C8—Etoposide—urinary bladder cancer	0.0203	0.0811	CbGbCtD
Pioglitazone—CYP2C9—Fluorouracil—urinary bladder cancer	0.017	0.0678	CbGbCtD
Pioglitazone—CYP2C9—Cisplatin—urinary bladder cancer	0.0144	0.0576	CbGbCtD
Pioglitazone—CYP2D6—Doxorubicin—urinary bladder cancer	0.00882	0.0353	CbGbCtD
Pioglitazone—CYP3A4—Etoposide—urinary bladder cancer	0.00823	0.0329	CbGbCtD
Pioglitazone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00561	0.0224	CbGbCtD
Pioglitazone—CYP2C19—urine—urinary bladder cancer	0.00321	0.108	CbGeAlD
Pioglitazone—Rosiglitazone—PPARG—urinary bladder cancer	0.00255	1	CrCbGaD
Pioglitazone—CYP2C9—urine—urinary bladder cancer	0.00249	0.0835	CbGeAlD
Pioglitazone—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.0024	1	CbGdCrCtD
Pioglitazone—CYP3A4—urine—urinary bladder cancer	0.0019	0.0637	CbGeAlD
Pioglitazone—CYP2D6—urine—urinary bladder cancer	0.00187	0.0627	CbGeAlD
Pioglitazone—PPARG—prostate gland—urinary bladder cancer	0.00153	0.0512	CbGeAlD
Pioglitazone—SLCO1B3—vagina—urinary bladder cancer	0.00151	0.0507	CbGeAlD
Pioglitazone—SLCO1B1—renal system—urinary bladder cancer	0.00121	0.0405	CbGeAlD
Pioglitazone—PPARG—epithelium—urinary bladder cancer	0.00112	0.0376	CbGeAlD
Pioglitazone—PPARG—smooth muscle tissue—urinary bladder cancer	0.00108	0.0363	CbGeAlD
Pioglitazone—PPARG—renal system—urinary bladder cancer	0.00104	0.0349	CbGeAlD
Pioglitazone—PPARG—urethra—urinary bladder cancer	0.00102	0.0343	CbGeAlD
Pioglitazone—SLCO1B1—female reproductive system—urinary bladder cancer	0.000965	0.0324	CbGeAlD
Pioglitazone—PPARG—female reproductive system—urinary bladder cancer	0.000833	0.0279	CbGeAlD
Pioglitazone—PTGS1—prostate gland—urinary bladder cancer	0.000815	0.0274	CbGeAlD
Pioglitazone—PPARG—vagina—urinary bladder cancer	0.000753	0.0253	CbGeAlD
Pioglitazone—PTGS1—seminal vesicle—urinary bladder cancer	0.00069	0.0232	CbGeAlD
Pioglitazone—CYP2C8—renal system—urinary bladder cancer	0.000685	0.023	CbGeAlD
Pioglitazone—PTGS1—epithelium—urinary bladder cancer	0.000599	0.0201	CbGeAlD
Pioglitazone—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000577	0.0194	CbGeAlD
Pioglitazone—CYP2C19—vagina—urinary bladder cancer	0.000569	0.0191	CbGeAlD
Pioglitazone—PTGS1—renal system—urinary bladder cancer	0.000556	0.0187	CbGeAlD
Pioglitazone—CYP2C8—female reproductive system—urinary bladder cancer	0.000549	0.0184	CbGeAlD
Pioglitazone—CYP2C8—vagina—urinary bladder cancer	0.000496	0.0167	CbGeAlD
Pioglitazone—CYP2C9—female reproductive system—urinary bladder cancer	0.000488	0.0164	CbGeAlD
Pioglitazone—PPARG—lymph node—urinary bladder cancer	0.000487	0.0163	CbGeAlD
Pioglitazone—CYP3A4—renal system—urinary bladder cancer	0.000464	0.0156	CbGeAlD
Pioglitazone—CYP2D6—renal system—urinary bladder cancer	0.000457	0.0153	CbGeAlD
Pioglitazone—PTGS1—female reproductive system—urinary bladder cancer	0.000445	0.0149	CbGeAlD
Pioglitazone—PTGS1—vagina—urinary bladder cancer	0.000403	0.0135	CbGeAlD
Pioglitazone—CYP3A4—female reproductive system—urinary bladder cancer	0.000372	0.0125	CbGeAlD
Pioglitazone—CYP2D6—female reproductive system—urinary bladder cancer	0.000366	0.0123	CbGeAlD
Pioglitazone—PTGS1—lymph node—urinary bladder cancer	0.00026	0.00874	CbGeAlD
Pioglitazone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000213	0.00178	CcSEcCtD
Pioglitazone—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000213	0.00177	CcSEcCtD
Pioglitazone—Cardiac failure—Epirubicin—urinary bladder cancer	0.000213	0.00177	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000212	0.00176	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000212	0.00176	CcSEcCtD
Pioglitazone—Infection—Gemcitabine—urinary bladder cancer	0.000212	0.00176	CcSEcCtD
Pioglitazone—Oedema—Fluorouracil—urinary bladder cancer	0.00021	0.00175	CcSEcCtD
Pioglitazone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00021	0.00175	CcSEcCtD
Pioglitazone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000209	0.00174	CcSEcCtD
Pioglitazone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000209	0.00174	CcSEcCtD
Pioglitazone—Infection—Fluorouracil—urinary bladder cancer	0.000208	0.00173	CcSEcCtD
Pioglitazone—Pain in extremity—Epirubicin—urinary bladder cancer	0.000208	0.00173	CcSEcCtD
Pioglitazone—Myalgia—Cisplatin—urinary bladder cancer	0.000207	0.00173	CcSEcCtD
Pioglitazone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000207	0.00172	CcSEcCtD
Pioglitazone—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000207	0.00172	CcSEcCtD
Pioglitazone—Anaemia—Etoposide—urinary bladder cancer	0.000206	0.00172	CcSEcCtD
Pioglitazone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000206	0.00172	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000206	0.00171	CcSEcCtD
Pioglitazone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000205	0.00171	CcSEcCtD
Pioglitazone—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000205	0.00171	CcSEcCtD
Pioglitazone—Discomfort—Cisplatin—urinary bladder cancer	0.000205	0.00171	CcSEcCtD
Pioglitazone—Increased appetite—Doxorubicin—urinary bladder cancer	0.000204	0.0017	CcSEcCtD
Pioglitazone—Urticaria—Thiotepa—urinary bladder cancer	0.000201	0.00168	CcSEcCtD
Pioglitazone—Malaise—Etoposide—urinary bladder cancer	0.000201	0.00168	CcSEcCtD
Pioglitazone—Breast disorder—Methotrexate—urinary bladder cancer	0.0002	0.00167	CcSEcCtD
Pioglitazone—Vertigo—Etoposide—urinary bladder cancer	0.0002	0.00167	CcSEcCtD
Pioglitazone—Oedema—Cisplatin—urinary bladder cancer	0.000199	0.00166	CcSEcCtD
Pioglitazone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000199	0.00166	CcSEcCtD
Pioglitazone—Infection—Cisplatin—urinary bladder cancer	0.000197	0.00164	CcSEcCtD
Pioglitazone—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000197	0.00164	CcSEcCtD
Pioglitazone—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000197	0.00164	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000196	0.00163	CcSEcCtD
Pioglitazone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000195	0.00162	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000194	0.00162	CcSEcCtD
Pioglitazone—Skin disorder—Cisplatin—urinary bladder cancer	0.000193	0.00161	CcSEcCtD
Pioglitazone—Insomnia—Gemcitabine—urinary bladder cancer	0.000193	0.00161	CcSEcCtD
Pioglitazone—Hypertension—Etoposide—urinary bladder cancer	0.000193	0.0016	CcSEcCtD
Pioglitazone—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000192	0.0016	CcSEcCtD
Pioglitazone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000192	0.0016	CcSEcCtD
Pioglitazone—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000192	0.0016	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000191	0.00159	CcSEcCtD
Pioglitazone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00019	0.00158	CcSEcCtD
Pioglitazone—Chest pain—Etoposide—urinary bladder cancer	0.00019	0.00158	CcSEcCtD
Pioglitazone—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00019	0.00158	CcSEcCtD
Pioglitazone—Insomnia—Fluorouracil—urinary bladder cancer	0.00019	0.00158	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000189	0.00157	CcSEcCtD
Pioglitazone—Discomfort—Etoposide—urinary bladder cancer	0.000188	0.00156	CcSEcCtD
Pioglitazone—Breast disorder—Epirubicin—urinary bladder cancer	0.000188	0.00156	CcSEcCtD
Pioglitazone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000187	0.00156	CcSEcCtD
Pioglitazone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000187	0.00156	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000184	0.00153	CcSEcCtD
Pioglitazone—Fatigue—Gemcitabine—urinary bladder cancer	0.000184	0.00153	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000183	0.00153	CcSEcCtD
Pioglitazone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000182	0.00152	CcSEcCtD
Pioglitazone—Asthenia—Thiotepa—urinary bladder cancer	0.000182	0.00151	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000181	0.00151	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000181	0.00151	CcSEcCtD
Pioglitazone—Infection—Etoposide—urinary bladder cancer	0.000181	0.00151	CcSEcCtD
Pioglitazone—Influenza—Epirubicin—urinary bladder cancer	0.000179	0.00149	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000178	0.00148	CcSEcCtD
Pioglitazone—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000177	0.00148	CcSEcCtD
Pioglitazone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000177	0.00148	CcSEcCtD
Pioglitazone—Skin disorder—Etoposide—urinary bladder cancer	0.000177	0.00147	CcSEcCtD
Pioglitazone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000177	0.00147	CcSEcCtD
Pioglitazone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000176	0.00147	CcSEcCtD
Pioglitazone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000176	0.00146	CcSEcCtD
Pioglitazone—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000175	0.00146	CcSEcCtD
Pioglitazone—Angina pectoris—Epirubicin—urinary bladder cancer	0.000175	0.00146	CcSEcCtD
Pioglitazone—Breast disorder—Doxorubicin—urinary bladder cancer	0.000174	0.00145	CcSEcCtD
Pioglitazone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000173	0.00144	CcSEcCtD
Pioglitazone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000173	0.00144	CcSEcCtD
Pioglitazone—Bronchitis—Epirubicin—urinary bladder cancer	0.000173	0.00144	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000171	0.00143	CcSEcCtD
Pioglitazone—Infestation—Methotrexate—urinary bladder cancer	0.000171	0.00142	CcSEcCtD
Pioglitazone—Infestation NOS—Methotrexate—urinary bladder cancer	0.000171	0.00142	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000169	0.00141	CcSEcCtD
Pioglitazone—Dizziness—Thiotepa—urinary bladder cancer	0.000168	0.0014	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000167	0.00139	CcSEcCtD
Pioglitazone—Urticaria—Fluorouracil—urinary bladder cancer	0.000166	0.00139	CcSEcCtD
Pioglitazone—Influenza—Doxorubicin—urinary bladder cancer	0.000166	0.00138	CcSEcCtD
Pioglitazone—Sweating—Methotrexate—urinary bladder cancer	0.000164	0.00137	CcSEcCtD
Pioglitazone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000164	0.00136	CcSEcCtD
Pioglitazone—Weight increased—Epirubicin—urinary bladder cancer	0.000163	0.00136	CcSEcCtD
Pioglitazone—Haematuria—Methotrexate—urinary bladder cancer	0.000163	0.00136	CcSEcCtD
Pioglitazone—Weight decreased—Epirubicin—urinary bladder cancer	0.000162	0.00135	CcSEcCtD
Pioglitazone—Dyspnoea—Etoposide—urinary bladder cancer	0.000162	0.00135	CcSEcCtD
Pioglitazone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000162	0.00135	CcSEcCtD
Pioglitazone—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000162	0.00135	CcSEcCtD
Pioglitazone—Infestation NOS—Epirubicin—urinary bladder cancer	0.00016	0.00133	CcSEcCtD
Pioglitazone—Infestation—Epirubicin—urinary bladder cancer	0.00016	0.00133	CcSEcCtD
Pioglitazone—Bronchitis—Doxorubicin—urinary bladder cancer	0.00016	0.00133	CcSEcCtD
Pioglitazone—Headache—Thiotepa—urinary bladder cancer	0.000159	0.00132	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000157	0.00131	CcSEcCtD
Pioglitazone—Fatigue—Etoposide—urinary bladder cancer	0.000157	0.00131	CcSEcCtD
Pioglitazone—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000155	0.0013	CcSEcCtD
Pioglitazone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000154	0.00129	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000154	0.00129	CcSEcCtD
Pioglitazone—Hepatitis—Methotrexate—urinary bladder cancer	0.000153	0.00128	CcSEcCtD
Pioglitazone—Sweating—Epirubicin—urinary bladder cancer	0.000153	0.00128	CcSEcCtD
Pioglitazone—Asthenia—Gemcitabine—urinary bladder cancer	0.000153	0.00127	CcSEcCtD
Pioglitazone—Haematuria—Epirubicin—urinary bladder cancer	0.000152	0.00127	CcSEcCtD
Pioglitazone—Pharyngitis—Methotrexate—urinary bladder cancer	0.000152	0.00127	CcSEcCtD
Pioglitazone—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000152	0.00126	CcSEcCtD
Pioglitazone—Weight increased—Doxorubicin—urinary bladder cancer	0.000151	0.00126	CcSEcCtD
Pioglitazone—Urethral disorder—Methotrexate—urinary bladder cancer	0.00015	0.00125	CcSEcCtD
Pioglitazone—Weight decreased—Doxorubicin—urinary bladder cancer	0.00015	0.00125	CcSEcCtD
Pioglitazone—Sinusitis—Epirubicin—urinary bladder cancer	0.00015	0.00125	CcSEcCtD
Pioglitazone—Feeling abnormal—Etoposide—urinary bladder cancer	0.00015	0.00125	CcSEcCtD
Pioglitazone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00015	0.00125	CcSEcCtD
Pioglitazone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000148	0.00123	CcSEcCtD
Pioglitazone—Infestation—Doxorubicin—urinary bladder cancer	0.000148	0.00123	CcSEcCtD
Pioglitazone—Visual impairment—Methotrexate—urinary bladder cancer	0.000148	0.00123	CcSEcCtD
Pioglitazone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000146	0.00122	CcSEcCtD
Pioglitazone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000146	0.00121	CcSEcCtD
Pioglitazone—Urticaria—Etoposide—urinary bladder cancer	0.000145	0.0012	CcSEcCtD
Pioglitazone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000144	0.0012	CcSEcCtD
Pioglitazone—Hepatitis—Epirubicin—urinary bladder cancer	0.000144	0.0012	CcSEcCtD
Pioglitazone—Eye disorder—Methotrexate—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Pioglitazone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Pioglitazone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Pioglitazone—Asthenia—Cisplatin—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Pioglitazone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Pioglitazone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000142	0.00119	CcSEcCtD
Pioglitazone—Sweating—Doxorubicin—urinary bladder cancer	0.000142	0.00118	CcSEcCtD
Pioglitazone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000142	0.00118	CcSEcCtD
Pioglitazone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000141	0.00118	CcSEcCtD
Pioglitazone—Haematuria—Doxorubicin—urinary bladder cancer	0.000141	0.00118	CcSEcCtD
Pioglitazone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000141	0.00118	CcSEcCtD
Pioglitazone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000141	0.00117	CcSEcCtD
Pioglitazone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000139	0.00116	CcSEcCtD
Pioglitazone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000139	0.00115	CcSEcCtD
Pioglitazone—Dizziness—Fluorouracil—urinary bladder cancer	0.000139	0.00115	CcSEcCtD
Pioglitazone—Visual impairment—Epirubicin—urinary bladder cancer	0.000138	0.00115	CcSEcCtD
Pioglitazone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000138	0.00115	CcSEcCtD
Pioglitazone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000136	0.00113	CcSEcCtD
Pioglitazone—Eye disorder—Epirubicin—urinary bladder cancer	0.000134	0.00112	CcSEcCtD
Pioglitazone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000134	0.00112	CcSEcCtD
Pioglitazone—Malnutrition—Methotrexate—urinary bladder cancer	0.000134	0.00111	CcSEcCtD
Pioglitazone—Headache—Gemcitabine—urinary bladder cancer	0.000134	0.00111	CcSEcCtD
Pioglitazone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000133	0.00111	CcSEcCtD
Pioglitazone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000133	0.00111	CcSEcCtD
Pioglitazone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000132	0.0011	CcSEcCtD
Pioglitazone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000132	0.0011	CcSEcCtD
Pioglitazone—Headache—Fluorouracil—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Pioglitazone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Pioglitazone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Pioglitazone—Asthenia—Etoposide—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Pioglitazone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Pioglitazone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00013	0.00109	CcSEcCtD
Pioglitazone—Immune system disorder—Epirubicin—urinary bladder cancer	0.00013	0.00108	CcSEcCtD
Pioglitazone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000129	0.00108	CcSEcCtD
Pioglitazone—Back pain—Methotrexate—urinary bladder cancer	0.000129	0.00108	CcSEcCtD
Pioglitazone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000128	0.00107	CcSEcCtD
Pioglitazone—Malnutrition—Epirubicin—urinary bladder cancer	0.000125	0.00104	CcSEcCtD
Pioglitazone—Diarrhoea—Etoposide—urinary bladder cancer	0.000125	0.00104	CcSEcCtD
Pioglitazone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00103	CcSEcCtD
Pioglitazone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000124	0.00103	CcSEcCtD
Pioglitazone—Anaemia—Methotrexate—urinary bladder cancer	0.000123	0.00103	CcSEcCtD
Pioglitazone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000123	0.00103	CcSEcCtD
Pioglitazone—Flatulence—Epirubicin—urinary bladder cancer	0.000123	0.00103	CcSEcCtD
Pioglitazone—Back pain—Epirubicin—urinary bladder cancer	0.000121	0.00101	CcSEcCtD
Pioglitazone—Malaise—Methotrexate—urinary bladder cancer	0.00012	0.001	CcSEcCtD
Pioglitazone—Dizziness—Etoposide—urinary bladder cancer	0.00012	0.001	CcSEcCtD
Pioglitazone—Muscle spasms—Epirubicin—urinary bladder cancer	0.00012	0.001	CcSEcCtD
Pioglitazone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00012	0.001	CcSEcCtD
Pioglitazone—Vertigo—Methotrexate—urinary bladder cancer	0.00012	0.001	CcSEcCtD
Pioglitazone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00012	0.000998	CcSEcCtD
Pioglitazone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000116	0.000966	CcSEcCtD
Pioglitazone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000116	0.000964	CcSEcCtD
Pioglitazone—Anaemia—Epirubicin—urinary bladder cancer	0.000116	0.000963	CcSEcCtD
Pioglitazone—Headache—Etoposide—urinary bladder cancer	0.000114	0.00095	CcSEcCtD
Pioglitazone—Flatulence—Doxorubicin—urinary bladder cancer	0.000114	0.00095	CcSEcCtD
Pioglitazone—Myalgia—Methotrexate—urinary bladder cancer	0.000114	0.000947	CcSEcCtD
Pioglitazone—Chest pain—Methotrexate—urinary bladder cancer	0.000114	0.000947	CcSEcCtD
Pioglitazone—Arthralgia—Methotrexate—urinary bladder cancer	0.000114	0.000947	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000113	0.000941	CcSEcCtD
Pioglitazone—Malaise—Epirubicin—urinary bladder cancer	0.000113	0.000939	CcSEcCtD
Pioglitazone—Discomfort—Methotrexate—urinary bladder cancer	0.000112	0.000936	CcSEcCtD
Pioglitazone—Vertigo—Epirubicin—urinary bladder cancer	0.000112	0.000936	CcSEcCtD
Pioglitazone—Back pain—Doxorubicin—urinary bladder cancer	0.000112	0.000932	CcSEcCtD
Pioglitazone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000111	0.000926	CcSEcCtD
Pioglitazone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000109	0.000908	CcSEcCtD
Pioglitazone—Infection—Methotrexate—urinary bladder cancer	0.000108	0.000902	CcSEcCtD
Pioglitazone—Hypertension—Epirubicin—urinary bladder cancer	0.000108	0.000899	CcSEcCtD
Pioglitazone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000107	0.000894	CcSEcCtD
Pioglitazone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000107	0.000891	CcSEcCtD
Pioglitazone—Anaemia—Doxorubicin—urinary bladder cancer	0.000107	0.000891	CcSEcCtD
Pioglitazone—Chest pain—Epirubicin—urinary bladder cancer	0.000106	0.000887	CcSEcCtD
Pioglitazone—Myalgia—Epirubicin—urinary bladder cancer	0.000106	0.000887	CcSEcCtD
Pioglitazone—Arthralgia—Epirubicin—urinary bladder cancer	0.000106	0.000887	CcSEcCtD
Pioglitazone—Skin disorder—Methotrexate—urinary bladder cancer	0.000106	0.000882	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000106	0.000881	CcSEcCtD
Pioglitazone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000105	0.000878	CcSEcCtD
Pioglitazone—Discomfort—Epirubicin—urinary bladder cancer	0.000105	0.000876	CcSEcCtD
Pioglitazone—Malaise—Doxorubicin—urinary bladder cancer	0.000104	0.000869	CcSEcCtD
Pioglitazone—Vertigo—Doxorubicin—urinary bladder cancer	0.000104	0.000866	CcSEcCtD
Pioglitazone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000102	0.00085	CcSEcCtD
Pioglitazone—Oedema—Epirubicin—urinary bladder cancer	0.000102	0.00085	CcSEcCtD
Pioglitazone—Infection—Epirubicin—urinary bladder cancer	0.000101	0.000844	CcSEcCtD
Pioglitazone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.0001	0.000834	CcSEcCtD
Pioglitazone—Hypertension—Doxorubicin—urinary bladder cancer	9.98e-05	0.000832	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.93e-05	0.000827	CcSEcCtD
Pioglitazone—Skin disorder—Epirubicin—urinary bladder cancer	9.91e-05	0.000826	CcSEcCtD
Pioglitazone—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.86e-05	0.000822	CcSEcCtD
Pioglitazone—Insomnia—Methotrexate—urinary bladder cancer	9.86e-05	0.000821	CcSEcCtD
Pioglitazone—Chest pain—Doxorubicin—urinary bladder cancer	9.85e-05	0.00082	CcSEcCtD
Pioglitazone—Arthralgia—Doxorubicin—urinary bladder cancer	9.85e-05	0.00082	CcSEcCtD
Pioglitazone—Myalgia—Doxorubicin—urinary bladder cancer	9.85e-05	0.00082	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.78e-05	0.000815	CcSEcCtD
Pioglitazone—Discomfort—Doxorubicin—urinary bladder cancer	9.73e-05	0.000811	CcSEcCtD
Pioglitazone—Dyspnoea—Methotrexate—urinary bladder cancer	9.72e-05	0.00081	CcSEcCtD
Pioglitazone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.44e-05	0.000786	CcSEcCtD
Pioglitazone—Oedema—Doxorubicin—urinary bladder cancer	9.44e-05	0.000786	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.41e-05	0.000784	CcSEcCtD
Pioglitazone—Fatigue—Methotrexate—urinary bladder cancer	9.4e-05	0.000783	CcSEcCtD
Pioglitazone—Infection—Doxorubicin—urinary bladder cancer	9.38e-05	0.000781	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.29e-05	0.000774	CcSEcCtD
Pioglitazone—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.26e-05	0.000771	CcSEcCtD
Pioglitazone—Insomnia—Epirubicin—urinary bladder cancer	9.23e-05	0.000769	CcSEcCtD
Pioglitazone—Skin disorder—Doxorubicin—urinary bladder cancer	9.17e-05	0.000764	CcSEcCtD
Pioglitazone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.12e-05	0.00076	CcSEcCtD
Pioglitazone—Dyspnoea—Epirubicin—urinary bladder cancer	9.09e-05	0.000758	CcSEcCtD
Pioglitazone—Feeling abnormal—Methotrexate—urinary bladder cancer	8.98e-05	0.000748	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.81e-05	0.000734	CcSEcCtD
Pioglitazone—Fatigue—Epirubicin—urinary bladder cancer	8.79e-05	0.000733	CcSEcCtD
Pioglitazone—Urticaria—Methotrexate—urinary bladder cancer	8.66e-05	0.000721	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.6e-05	0.000716	CcSEcCtD
Pioglitazone—Insomnia—Doxorubicin—urinary bladder cancer	8.54e-05	0.000711	CcSEcCtD
Pioglitazone—Dyspnoea—Doxorubicin—urinary bladder cancer	8.41e-05	0.000701	CcSEcCtD
Pioglitazone—Feeling abnormal—Epirubicin—urinary bladder cancer	8.41e-05	0.0007	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.15e-05	0.000679	CcSEcCtD
Pioglitazone—Fatigue—Doxorubicin—urinary bladder cancer	8.14e-05	0.000678	CcSEcCtD
Pioglitazone—Urticaria—Epirubicin—urinary bladder cancer	8.1e-05	0.000675	CcSEcCtD
Pioglitazone—Hypersensitivity—Methotrexate—urinary bladder cancer	8.03e-05	0.000669	CcSEcCtD
Pioglitazone—Asthenia—Methotrexate—urinary bladder cancer	7.82e-05	0.000652	CcSEcCtD
Pioglitazone—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.78e-05	0.000648	CcSEcCtD
Pioglitazone—Hypersensitivity—Epirubicin—urinary bladder cancer	7.52e-05	0.000626	CcSEcCtD
Pioglitazone—Urticaria—Doxorubicin—urinary bladder cancer	7.5e-05	0.000625	CcSEcCtD
Pioglitazone—Diarrhoea—Methotrexate—urinary bladder cancer	7.46e-05	0.000621	CcSEcCtD
Pioglitazone—Asthenia—Epirubicin—urinary bladder cancer	7.32e-05	0.00061	CcSEcCtD
Pioglitazone—Dizziness—Methotrexate—urinary bladder cancer	7.21e-05	0.000601	CcSEcCtD
Pioglitazone—Diarrhoea—Epirubicin—urinary bladder cancer	6.98e-05	0.000582	CcSEcCtD
Pioglitazone—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.95e-05	0.000579	CcSEcCtD
Pioglitazone—Headache—Methotrexate—urinary bladder cancer	6.83e-05	0.000569	CcSEcCtD
Pioglitazone—Asthenia—Doxorubicin—urinary bladder cancer	6.77e-05	0.000564	CcSEcCtD
Pioglitazone—Dizziness—Epirubicin—urinary bladder cancer	6.75e-05	0.000562	CcSEcCtD
Pioglitazone—Diarrhoea—Doxorubicin—urinary bladder cancer	6.46e-05	0.000538	CcSEcCtD
Pioglitazone—Headache—Epirubicin—urinary bladder cancer	6.39e-05	0.000532	CcSEcCtD
Pioglitazone—Dizziness—Doxorubicin—urinary bladder cancer	6.24e-05	0.00052	CcSEcCtD
Pioglitazone—Headache—Doxorubicin—urinary bladder cancer	5.91e-05	0.000493	CcSEcCtD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.3e-05	0.000485	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GSTT1—urinary bladder cancer	3.29e-05	0.000484	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—TYMP—urinary bladder cancer	3.29e-05	0.000484	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—RHOA—urinary bladder cancer	3.28e-05	0.000483	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.24e-05	0.000477	CbGpPWpGaD
Pioglitazone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.24e-05	0.000477	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	3.2e-05	0.000472	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	3.2e-05	0.000472	CbGpPWpGaD
Pioglitazone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.19e-05	0.00047	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.16e-05	0.000465	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NAT1—urinary bladder cancer	3.13e-05	0.000461	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	3.13e-05	0.000461	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.11e-05	0.000458	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.08e-05	0.000453	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—ERBB2—urinary bladder cancer	3.04e-05	0.000447	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	3.03e-05	0.000447	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	3.01e-05	0.000443	CbGpPWpGaD
Pioglitazone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.98e-05	0.000438	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—NAT2—urinary bladder cancer	2.97e-05	0.000438	CbGpPWpGaD
Pioglitazone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.93e-05	0.000432	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	2.89e-05	0.000425	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	2.88e-05	0.000425	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.88e-05	0.000424	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.88e-05	0.000424	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	2.86e-05	0.000421	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.85e-05	0.00042	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.85e-05	0.00042	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.8e-05	0.000413	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—NQO1—urinary bladder cancer	2.73e-05	0.000403	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	2.72e-05	0.000401	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.71e-05	0.000399	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—NCOR1—urinary bladder cancer	2.69e-05	0.000397	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	2.67e-05	0.000394	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	2.67e-05	0.000393	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	2.67e-05	0.000393	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	2.66e-05	0.000391	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.65e-05	0.000391	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.65e-05	0.000391	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.63e-05	0.000387	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.61e-05	0.000384	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—MMP9—urinary bladder cancer	2.61e-05	0.000384	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	2.59e-05	0.000381	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.59e-05	0.000381	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	2.58e-05	0.000379	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.57e-05	0.000378	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.55e-05	0.000376	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—ERCC2—urinary bladder cancer	2.53e-05	0.000373	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	2.48e-05	0.000366	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—EP300—urinary bladder cancer	2.47e-05	0.000364	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	2.46e-05	0.000362	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	2.46e-05	0.000362	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	2.43e-05	0.000358	CbGpPWpGaD
Pioglitazone—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.43e-05	0.000357	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—SRC—urinary bladder cancer	2.4e-05	0.000354	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—HPGDS—urinary bladder cancer	2.38e-05	0.00035	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—ENO2—urinary bladder cancer	2.38e-05	0.00035	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.37e-05	0.000349	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.37e-05	0.000349	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.36e-05	0.000348	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	2.35e-05	0.000346	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.35e-05	0.000346	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.31e-05	0.000341	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	2.31e-05	0.00034	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.3e-05	0.000339	CbGpPWpGaD
Pioglitazone—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	2.29e-05	0.000337	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GSTP1—urinary bladder cancer	2.28e-05	0.000336	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.27e-05	0.000334	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	2.24e-05	0.000329	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.22e-05	0.000327	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.21e-05	0.000325	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.18e-05	0.000321	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	2.17e-05	0.00032	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.16e-05	0.000318	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.15e-05	0.000317	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.13e-05	0.000314	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.12e-05	0.000313	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—TYMS—urinary bladder cancer	2.12e-05	0.000312	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—ESR1—urinary bladder cancer	2.12e-05	0.000312	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—EGFR—urinary bladder cancer	2.11e-05	0.00031	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—NCOR1—urinary bladder cancer	2.1e-05	0.000309	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GSTM1—urinary bladder cancer	2.1e-05	0.000309	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.09e-05	0.000308	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.04e-05	0.0003	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GPX1—urinary bladder cancer	2.01e-05	0.000295	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—TNF—urinary bladder cancer	2e-05	0.000295	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—KRAS—urinary bladder cancer	1.99e-05	0.000293	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.98e-05	0.000292	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—ERCC2—urinary bladder cancer	1.97e-05	0.00029	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.92e-05	0.000283	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.91e-05	0.000282	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.9e-05	0.00028	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.89e-05	0.000279	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.88e-05	0.000277	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.88e-05	0.000277	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.86e-05	0.000274	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.86e-05	0.000273	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.85e-05	0.000273	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.82e-05	0.000268	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.82e-05	0.000268	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.8e-05	0.000264	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.76e-05	0.000259	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.74e-05	0.000257	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.74e-05	0.000256	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.73e-05	0.000255	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.73e-05	0.000254	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.72e-05	0.000253	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.71e-05	0.000252	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.69e-05	0.000249	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.69e-05	0.000249	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.67e-05	0.000246	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.66e-05	0.000244	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.66e-05	0.000244	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.65e-05	0.000243	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.65e-05	0.000243	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.62e-05	0.000239	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.6e-05	0.000235	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.58e-05	0.000233	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.58e-05	0.000232	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.56e-05	0.00023	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000228	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.55e-05	0.000228	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.55e-05	0.000228	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.53e-05	0.000226	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.53e-05	0.000226	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.53e-05	0.000225	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.49e-05	0.000219	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.48e-05	0.000219	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.48e-05	0.000218	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.47e-05	0.000216	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.47e-05	0.000216	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.47e-05	0.000216	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.46e-05	0.000215	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.46e-05	0.000215	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.44e-05	0.000212	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.43e-05	0.00021	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.41e-05	0.000207	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	1.38e-05	0.000204	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.38e-05	0.000203	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.37e-05	0.000202	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.37e-05	0.000202	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.36e-05	0.000201	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.36e-05	0.0002	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.35e-05	0.000199	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.33e-05	0.000196	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.31e-05	0.000193	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.3e-05	0.000191	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.26e-05	0.000186	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.26e-05	0.000186	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.25e-05	0.000184	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.25e-05	0.000184	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.24e-05	0.000183	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.24e-05	0.000182	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.22e-05	0.00018	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.21e-05	0.000178	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	1.21e-05	0.000178	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.2e-05	0.000177	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.19e-05	0.000176	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000174	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—PTGS2—urinary bladder cancer	1.18e-05	0.000174	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—EP300—urinary bladder cancer	1.15e-05	0.00017	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.14e-05	0.000168	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	0.000167	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.1e-05	0.000163	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—MYC—urinary bladder cancer	1.1e-05	0.000162	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.07e-05	0.000158	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.05e-05	0.000155	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.05e-05	0.000154	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.03e-05	0.000152	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.03e-05	0.000152	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—PTEN—urinary bladder cancer	1.03e-05	0.000152	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.02e-05	0.00015	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.01e-05	0.000149	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.01e-05	0.000148	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.98e-06	0.000147	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—EP300—urinary bladder cancer	9.82e-06	0.000145	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.77e-06	0.000144	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	9.59e-06	0.000141	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	9.48e-06	0.00014	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	9.48e-06	0.00014	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.34e-06	0.000138	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	9.3e-06	0.000137	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	9.21e-06	0.000136	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	9.08e-06	0.000134	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	8.91e-06	0.000131	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.91e-06	0.000131	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.89e-06	0.000131	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	8.56e-06	0.000126	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.52e-06	0.000125	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	8.47e-06	0.000125	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	8.46e-06	0.000125	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	8.46e-06	0.000125	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	8.4e-06	0.000124	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	8.38e-06	0.000123	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—PTGS2—urinary bladder cancer	8.27e-06	0.000122	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.24e-06	0.000121	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.24e-06	0.000121	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.12e-06	0.00012	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	8.11e-06	0.000119	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	8.1e-06	0.000119	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.99e-06	0.000118	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	7.96e-06	0.000117	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	7.87e-06	0.000116	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	7.81e-06	0.000115	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	7.78e-06	0.000115	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	7.78e-06	0.000115	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—EP300—urinary bladder cancer	7.74e-06	0.000114	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	7.72e-06	0.000114	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	7.72e-06	0.000114	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	7.48e-06	0.00011	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	7.45e-06	0.00011	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	7.39e-06	0.000109	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	7.32e-06	0.000108	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	7.25e-06	0.000107	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—PTEN—urinary bladder cancer	7.22e-06	0.000106	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—EP300—urinary bladder cancer	6.88e-06	0.000101	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	6.88e-06	0.000101	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	6.82e-06	0.0001	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	6.79e-06	0.0001	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.64e-06	9.78e-05	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	6.53e-06	9.61e-05	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	6.06e-06	8.93e-05	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	5.83e-06	8.58e-05	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	5.58e-06	8.21e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.54e-06	8.16e-05	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	5.53e-06	8.14e-05	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.36e-06	7.89e-05	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.34e-06	7.87e-05	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.31e-06	7.82e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.15e-06	7.58e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.09e-06	7.49e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.09e-06	7.49e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.87e-06	7.18e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.78e-06	7.05e-05	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	4.77e-06	7.03e-05	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.66e-06	6.86e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.5e-06	6.62e-05	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.45e-06	6.55e-05	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.39e-06	6.46e-05	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.35e-06	6.41e-05	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.16e-06	6.13e-05	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.97e-06	5.84e-05	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.83e-06	5.64e-05	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.79e-06	5.59e-05	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.65e-06	5.37e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.65e-06	5.37e-05	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.62e-06	5.33e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.5e-06	5.16e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.87e-06	4.22e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.5e-06	3.68e-05	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.39e-06	3.51e-05	CbGpPWpGaD
